Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 9, 2000, Pages 1075-1083

  Fuchs, B ^a   Breithaupt Grogler K ^b   Belz, G G ^b   Roll, S ^b   Malerczyk, C ^b   Herrmann, V ^b   Spahn Langguth, H ^c   Mutschler, E ^d  

^a GOETHE UNIVERSITY   (Germany)

^b ZeKaPha GmbH   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; CANDESARTAN HEXETIL; LOSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; HYSTERESIS; MALE; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0033797928     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001774994     Document Type: Article

References (23)

1. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension
2. Angiotensin II antagonism, radioligand receptor/chemical assays following candesartan cilexetil in man
3. Inhibition of angiotensin II pressor response and ex-vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers
4. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system
5. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
6. Characterisation of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
7. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
8. Antihypertensive effects of candesartan cilexetil, enalapril and placebo
9. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
10. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension
11. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
12. 1 antagonist, candesartan (CV-11974), with the angiotensin II receptor
13. A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypotheses of a receptor activation mechanism
14. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man
15. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling
16. 1 receptor
17. Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors
18. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
19. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-((2'-(1H-tetrazol-5-y1)bipheny1-4-y1)methy1) -1H-benzimidazole-7-carboxylic acid (CV-11974) and its prodrug, 1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4- yl) methyl)-1H-benzimidazole-7-carboxylate (TCV-116)
20. A radioreceptor assay for the analysis of AT 1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites
21. Angiotensin II receptors and angiotensin II receptor antagonists